Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genetic analyses of the electrocardiographic QT interval and its components identify additional loci and pathways

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genotype-phenotype correlation in arrhythmogenic right ventricular cardiomyopathy-risk of arrhythmias and heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To evaluate the association between PCSK9 predicted loss-of-function (pLoF) variants and glycemic traits, hepatobiliary function, and neurocognitive traits.

RESEARCH DESIGN AND METHODS: We identified carriers of PCSK9 pLoF variants in UK Biobank exome sequencing data. We assessed the aggregate effects of these variants on lipid and lipoprotein traits, which served as a positive control. Association of PCSK9 pLoF carrier status and glycemic traits, hepatobiliary function, and neurocognitive traits was then evaluated as a measure for adverse effects.

RESULTS: We identified 374 individuals carrying one of 41 unique PCSK9 pLoF variants. As expected, we found that PCSK9 pLoF carriers had significantly lower LDL cholesterol C levels (P = 7.4 × 10-55) and apolipoprotein B levels (P = 7.6 × 10-50) than did noncarriers. However, we found no significant associations between pLoF carrier status and glycemic traits, hepatobiliary function, and neurocognitive traits (P > 0.05).

CONCLUSIONS: Our results do not support adverse effects of PCSK9 pLoF variants on glycemic traits, hepatobiliary function, or neurocognitive traits.

OriginalsprogEngelsk
TidsskriftDiabetes Care
Vol/bind45
Udgave nummer1
Sider (fra-til)251-254
Antal sider4
ISSN1935-5548
DOI
StatusUdgivet - 1 jan. 2022

Bibliografisk note

© 2021 by the American Diabetes Association.

ID: 75303633